Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Evaluation of Lymphocyte Activation Gene3 (Lag-3) on Regulatory T Cells in Patients With Multiple Sclerosis by Intervention Effect of Fingolimod

Summary: A study found MS drug fingolimod boosts immune cells, potentially improving treatment outcomes. #MultipleSclerosis #Immunotherapy

Sedaghat N1 ; Zarkeshesfahani SH2 ; Alsahebfosoul F3 ; Etemadifar M4 ; Ostadi V5 ; Kianpour F5 ; Akbari M6
Authors

Source: Journal of Isfahan Medical School Published:2016

Abstract

Background: Regulatory CD4+Foxp3+ T cells (Tregs) play an important role in the prevention of autoimmune disease. It is also suggested that in multiple sclerosis (MS), a central nervous system disease, an aberrant Treg function may play a role. Lymphocyte activation gene3 (LAG-3) as a surface marker of Treg cells with negative regulation of the immune system can effectively encounter with effector lymphocytes. In this study, we evaluated frequency of CD4+Foxp3+LAG-3+ T cells before and after treatment with Fingolimod. Methods: Blood samples was obtained from 20 patients with multiple sclerosis before and after 1 months of Fingolimod treatment, and from 12 age-matched healthy control subjects. Then pripheral blood mononuclear cell (PBMCs) were isolated and the frequency of Treg cells expressing LAG-3 were determined by flowcytometry. Findings: The frequency of CD4+Foxp3+LAG3+ T cells in the peripheral blood of MS patients was increased when compared to baseline (P = 0.005). Conclusion: Our findings suggested that Fingolimod not only increases CD4+Foxp3+ Treg cells, but also is able to enhance expression of LAG-3 on their surface. This is a new finding for the Fingolimod on the immune system. © 2016, Journal of Isfahan Medical School. All rights reserved.
Related Docs
View other Related Docs
1. Increased Expression of Lymphocyte Activation Gene-3 by Regulatory T Cells in Multiple Sclerosis Patients With Fingolimod Treatment; [Multiple Sikleroz Hastalarinda Fingolimod Tedavisi Sonucu Duzenleyici T Hucrelerinde Lenfosit Aktivasyon Gen-3 Ekspresyonunda Artis], Turkish Journal of Immunology (2019)
2. Biased Treg/Th17 Balance Away From Regulatory Toward Inflammatory Phenotype in Relapsed Multiple Sclerosis and Its Correlation With Severity of Symptoms, Journal of Neuroimmunology (2013)
3. The Role of Immune Regulatory Molecules in Multiple Sclerosis, Journal of Neuroimmunology (2019)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (9)
Vahid Shaygannejad (5)
Evaluation of Lymphocyte Activation Gene3 (Lag-3) on Regulatory T Cells in Patients With Multiple Sclerosis by Intervention Effect of Fingolimod
Other Related Docs
4. The Role of Non-Hla Single Nucleotide Polymorphisms in Multiple Sclerosis Susceptibility, Journal of Neuroimmunology (2010)
5. Evaluation of Plasma Soluble Cd137 Level in Relapsing-Remitting Multiple Sclerosis Patients in Comparison With Healthy Controls in Isfahan Province, Iran, Neurology Asia (2020)
6. Silymarin Restores Regulatory T Cells (Tregs) Function in Multiple Sclerosis (Ms) Patients in Vitro, Inflammation (2019)
7. Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients, International Journal of Preventive Medicine (2015)
8. The Levels of Soluble Forms of Cd21 and Cd83 in Multiple Sclerosis, Journal of Neuroimmunology (2018)
9. Upregulation of Cd4+ T-Cell Derived Mir-223 in the Relapsing Phase of Multiple Sclerosis Patients, Cell Journal (2016)
10. Decreased Expression of Sema3a, an Immune Modulator, in Blood Sample of Multiple Sclerosis Patients, Gene (2017)
11. Toll Like Receptor 2 and 4 Expression in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients, Iranian Journal of Immunology (2014)
12. Evaluation of Soluble Human Leukocyte Antigen-G (Shla-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2015)
13. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
14. Comparison of Follicular T Helper Cells, Monocytes, and T Cells Priming Between Newly Diagnosed and Rituximab-Treated Ms Patients and Healthy Controls, Research in Pharmaceutical Sciences (2022)
15. The Effect of Plasma Exchange on the Expression of Foxp3 and Rorc2 in Relapsed Multiple Sclerosis Patients, Iranian Journal of Immunology (2015)
16. Can Plasma Exchange Therapy Induce Regulatory T Lymphocytes in Multiple Sclerosis Patients?, Clinical and Experimental Immunology (2012)
17. The Frequency of Varicella-Zoster Virus Infection in Patients With Multiple Sclerosis Receiving Fingolimod, Journal of Neuroimmunology (2019)
18. Assessment of the Impact of Interferon-ß and Rituximab on Nlrp3 and Aim2 Expression and Il-1Β Levels in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2025)
19. Does Lipoic Acid Consumption Affect the Cytokine Profile in Multiple Sclerosis Patients: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial, NeuroImmunoModulation (2014)
20. Evaluation of Plasma Osteopontin Level in Relapsing- Remitting Multiple Sclerosis Patients Compared to Healthy Subjects in Isfahan Province, International Journal of Neuroscience (2020)